動物抗生素和抗菌劑市場機會、成長動力、產業趨勢分析及 2025 - 2034 年預測

2024 年全球動物抗生素和抗菌劑市場價值為 50 億美元，預計 2025 年至 2034 年期間的複合年成長率為 4.3%。這一成長主要得益於威脅動物健康的人畜共患疾病的流行率不斷上升，以及在牲畜消費不斷增加的世界中對食品安全的需求日益增加。尤其是發展中國家，畜牧業正在蓬勃發展，從而更多地採取感染預防措施並改善動物健康管理。全球人口的成長以及對動物性蛋白質需求的相應增加，加劇了對可靠的抗生素和抗菌劑的需求，以維持牲畜的健康和生產力。此外，研發投入的不斷增加刺激了藥物配方的創新，提高了療效，同時最大限度地減少了不良副作用，進一步促進了市場擴張。獸醫基礎設施的進步和對預防性動物保健的更多重視為製造商引入尖端抗菌解決方案創造了有利可圖的機會，從而推動了預測期內的持續成長。

市場依產品類型細分為氨基糖苷類、四環素類、青黴素類、磺胺類、林可醯胺類、氟喹諾酮類、大環內酯類、頭孢菌素類等抗生素及抗菌劑。其中，四環素類藥物預計在預測期內的複合年成長率為4.6%。由於價格低廉且功效廣，它們成為治療牲畜和伴侶動物各種感染（包括呼吸道和胃腸道疾病）的熱門選擇。

市場根據動物類型進一步分為伴侶動物和牲畜動物。 2024 年，畜牧業佔 58.1%。該領域包括牛、豬、家禽、魚和其他牲畜。隨著城市化和全球飲食模式的轉變，動物產品的消費量不斷增加，推動了對保護牲畜免受感染的抗生素的需求。隨著消費者越來越意識到維持動物族群健康對於預防疾病爆發的重要性，對加強牲畜健康服務的關注也日益加強。強力的疾病控制措施的需求導致抗生素的使用增加，大大促進了市場擴張。

在美國，動物抗生素和抗菌藥物市場在 2024 年創造了 18 億美元的產值。該國先進的獸醫基礎設施、高寵物擁有率以及成熟的畜牧業推動了對抗生素和抗菌藥物的需求。動物保健領域的投資不斷增加，加上產品註冊和批准數量的增加，繼續推動市場成長。由於美國注重提高動物健康狀況和防止人畜共通傳染病的傳播，它仍然是市場上的重要參與者。

目錄

第1章：方法論與範圍

第2章：執行摘要

第3章：行業洞察

• 產業生態系統分析
• 產業衝擊力
  • 成長動力
    • 寵物擁有率不斷提高
    • 擴大畜牧業生產
    • 研發經費增加
    • 動物保健意識的不斷增強刺激了預防性治療的需求
  • 產業陷阱與挑戰
    • 治療的不良反應
    • 嚴格的監管要求
• 成長潛力分析
• 監管格局
• 未來市場趨勢
• 波特的分析
• PESTEL分析

第4章：競爭格局

• 介紹
• 公司矩陣分析
• 主要市場參與者的競爭分析
• 競爭定位矩陣
• 策略儀表板

第5章：市場估計與預測：按產品，2021 年至 2034 年

• 主要趨勢
• 青黴素
• 四環素類
• 磺胺類藥物
• 大環內酯類
• 氨基糖苷類
• 林可醯胺類
• 氟喹諾酮類藥物
• 頭孢菌素類
• 其他抗生素和抗菌產品

第6章：市場估計與預測：依動物類型，2021 年至 2034 年

• 主要趨勢
• 伴侶動物
  • 狗
  • 貓
  • 馬匹
  • 其他伴侶動物
• 牲畜
  • 牛
  • 豬
  • 家禽
  • 魚
  • 其他牲畜

第7章：市場估計與預測：依交付方式，2021 年至 2034 年

• 主要趨勢
• 口服
• 外用
• 注射
• 其他交付方式

第8章：市場估計與預測：按配銷通路，2021 年至 2034 年

• 主要趨勢
• 獸醫院藥房
• 零售藥局
• 電子商務

第9章：市場估計與預測：按地區，2021 年至 2034 年

• 主要趨勢
• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 英國
  • 法國
  • 西班牙
  • 義大利
  • 荷蘭
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
• 中東和非洲
  • 南非
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國

第10章：公司簡介

• AdvaCare Pharma
• Boehringer Ingelheim International
• Ceva
• Dechra
• Meiji Holdings
• Merck & Co.
• Vetoquinol
• Virbac
• Zoetis
• Zovixpharma

The Global Animal Antibiotics and Antimicrobials Market was valued at USD 5 billion in 2024 and is expected to grow at a CAGR of 4.3% between 2025 and 2034. This growth is primarily driven by the rising prevalence of zoonotic diseases that threaten animal health and the increasing need for food safety in a world where livestock consumption is escalating. Developing nations, in particular, are witnessing a surge in livestock farming, leading to greater adoption of infection prevention measures and improvements in animal health management. The growing global population and the corresponding rise in demand for animal-based protein have intensified the need for reliable antibiotics and antimicrobials to maintain livestock health and productivity. Additionally, rising investments in research and development have spurred innovations in drug formulations that enhance effectiveness while minimizing adverse side effects, further bolstering market expansion. Advancements in veterinary infrastructure and a greater emphasis on preventive animal healthcare have created lucrative opportunities for manufacturers to introduce cutting-edge antimicrobial solutions, driving consistent growth over the forecast period.

The market is segmented by product type into aminoglycosides, tetracyclines, penicillins, sulfonamides, lincosamides, fluoroquinolones, macrolides, cephalosporins, and other antibiotics and antimicrobial agents. Among these, tetracyclines are expected to grow at a CAGR of 4.6% during the forecast period. Their affordability and broad-spectrum efficacy make them a popular choice for managing a variety of infections, including respiratory and gastrointestinal conditions, across both livestock and companion animals.

The market is further divided by animal type into companion animals and livestock animals. The livestock segment held a 58.1% share in 2024. This segment encompasses cattle, swine, poultry, fish, and other livestock. With urbanization progressing and dietary patterns shifting globally, the consumption of animal-based products is increasing, driving demand for antibiotics to safeguard livestock from infections. As consumers become more aware of the importance of maintaining healthy animal populations to prevent disease outbreaks, the focus on enhancing livestock health services has intensified. The need for robust disease control measures has led to an uptick in the adoption of antibiotics, contributing significantly to market expansion.

In the U.S., the Animal Antibiotics and Antimicrobials Market generated USD 1.8 billion in 2024. The country's advanced veterinary infrastructure, high rates of pet ownership, and well-established livestock industry have fueled the demand for antibiotics and antimicrobials. Rising investments in animal healthcare, coupled with an increasing number of product registrations and approvals, continue to drive market growth. The U.S. remains a prominent player in the market due to its focus on enhancing animal health outcomes and preventing the spread of zoonotic diseases.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definition
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing pet ownership rate
    • 3.2.1.2 Expanding livestock production
    • 3.2.1.3 Rising research and development funding
    • 3.2.1.4 Growing awareness of animal healthcare spurring demand for preventive treatment
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 Adverse effects of treatments
    • 3.2.2.2 Stringent regulatory requirements
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Future market trends
• 3.6 Porter's analysis
• 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Competitive analysis of major market players
• 4.4 Competitive positioning matrix
• 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product, 2021 – 2034 ($ Mn)

• 5.1 Key trends
• 5.2 Penicillins
• 5.3 Tetracyclines
• 5.4 Sulfonamides
• 5.5 Macrolides
• 5.6 Aminoglycosides
• 5.7 Lincosamides
• 5.8 Fluoroquinolones
• 5.9 Cephalosporins
• 5.10 Other antibiotics and antimicrobial products

Chapter 6 Market Estimates and Forecast, By Animal Type, 2021 – 2034 ($ Mn)

• 6.1 Key trends
• 6.2 Companion animals
  • 6.2.1 Dogs
  • 6.2.2 Cats
  • 6.2.3 Horses
  • 6.2.4 Other companion animals
• 6.3 Livestock animals
  • 6.3.1 Cattle
  • 6.3.2 Swine
  • 6.3.3 Poultry
  • 6.3.4 Fish
  • 6.3.5 Other livestock animals

Chapter 7 Market Estimates and Forecast, By Mode of Delivery, 2021 – 2034 ($ Mn)

• 7.1 Key trends
• 7.2 Oral
• 7.3 Topical
• 7.4 Injections
• 7.5 Other modes of delivery

Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2021 – 2034 ($ Mn)

• 8.1 Key trends
• 8.2 Veterinary hospital pharmacy
• 8.3 Retail pharmacy
• 8.4 E-commerce

Chapter 9 Market Estimates and Forecast, By Region, 2021 – 2034 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Netherlands
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 India
  • 9.4.3 Japan
  • 9.4.4 Australia
  • 9.4.5 South Korea
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Argentina
• 9.6 Middle East and Africa
  • 9.6.1 South Africa
  • 9.6.2 Saudi Arabia
  • 9.6.3 UAE

Chapter 10 Company Profiles

• 10.1 AdvaCare Pharma
• 10.2 Boehringer Ingelheim International
• 10.3 Ceva
• 10.4 Dechra
• 10.5 Meiji Holdings
• 10.6 Merck & Co.
• 10.7 Vetoquinol
• 10.8 Virbac
• 10.9 Zoetis
• 10.10 Zovixpharma